Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad, Puma Biotechnology, and Dyax
NEW YORK, October 14, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Puma Biotechnology, Inc. (NYSE: PBYI), and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences Inc. Research Report
On October 9, 2013, Gilead Sciences Inc. (Gilead) announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early. According to Gilead, it has already informed the US Food and Drug Administration about its plan to end the study, which came in after the recommendation by an independent Data Monitoring Committee (DMC) that was based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving rituximab alone. Gilead reported that the safety profile of idelalisib was acceptable and consistent with prior experience in combination with rituximab in previously treated CLL. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9898_GILD]
Celgene Corporation Research Report
On October 3, 2013, Celgene Corporation (Celgene) reported that its wholly owned subsidiary, Celgene International Sàrl (Celgene International), has released results of pre-specified sub-analyses from ESTEEM 1 on nail and scalp psoriasis, as well as health-related quality-of-life outcomes, from the Company's first phase III study in psoriasis. Celgene International presented the study results at the 22nd Congress of the European Academy of Dermatology and Venereology annual meeting in Istanbul, Turkey. Professor Kristian Reich, M.D., SCIderm Research Institute and Dermatologikum, Hamburg, Germany, commented, "These analyses demonstrate that apremilast may improve these conditions and may offer a much-needed new oral treatment option for psoriasis patients. Moreover, the encouraging health-related quality-of-life findings suggest that long-term treatment with oral apremilast may improve the mental and physical well-being of these patients." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/7f47_CELG]
Ariad Pharmaceuticals Inc. Research Report
On October 9, 2013, ARIAD Pharmaceuticals Inc. (Ariad) announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig (ponatinib) and actions that it is taking following consultations with the US Food and Drug Administration (FDA). Harvey J. Berger, M.D., Chairman and CEO of Ariad, stated, "We believe that the actions we are taking will help us ensure the most appropriate and safe use of Iclusig. With two years of follow up, we have learned a great deal about both the efficacy and safety of Iclusig in patients with Philadelphia-positive leukemias." Berger continued, "We are focused first and foremost on the needs of cancer patients - to have new medicines that provide both safe and effective treatment of their malignancies. Our unwavering commitment to patients has led us to promptly take the steps we have outlined." The Full Research Report on ARIAD Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/161c_ARIA]
Puma Biotechnology, Inc. Research Report
On October 4, 2013, Puma Biotechnology, Inc. (Puma Biotechnology) announced that it initiated a Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). Puma Biotechnology reported that the Phase II basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating HER2 mutations. Alan H. Auerbach, CEO and President, Puma Biotechnology, commented, "It is estimated that approximately 2-10 percent of patients with solid tumors have a HER2 mutation. Preclinical data suggests that neratinib potently inhibits the activity of these cancer-driving mutations, which could translate into clinical benefit for these patients. We are pleased to initiate this basket study in order to further investigate the efficacy of neratinib in these patients with a particular unmet medical need." Auerbach added, "We anticipate that we may get an initial indication on the efficacy of neratinib in these mutation-positive patients by late this year or early next year and that we may be able to expand this trial with additional patients and additional cohorts during that same time period." The Full Research Report on Puma Biotechnology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4d27_PBYI]
Dyax Corp. Research Report
On October 9, 2013, Dyax Corp. (Dyax) announced the pricing of an underwritten public offering of 9.2 million shares of its common stock, offered at a price to the public of $6.50 per share. According to Dyax, gross proceeds from the offering are expected to be $60 million, before deducting the underwriting discount and other estimated offering expenses payable by the Company, and the offering is expected to close on or about October 15, 2013, subject to customary closing conditions. Dyax further reported that it intends to use the net proceeds from this offering to fund research and development activities, including the development of DX-2930, a therapeutic candidate for the prophylactic treatment of hereditary angioedema (HAE), and for general corporate purposes. The Full Research Report on Dyax Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/58ae_DYAX]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner